Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing-Reference-Cited by-同舟云学术

Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing

Published:2024-02-13 Issue:1 Volume:12 Page:1-11
ISSN:2167-8707
Container-title:Expert Opinion on Orphan Drugs
language:en
Short-container-title:Expert Opinion on Orphan Drugs

Author:

Rawson Nigel S B.¹²³,Adams John²⁴

Affiliation:

1. Canadian Health Policy Institute, Toronto, Ontario, Canada

2. Macdonald-Laurier Institute, Ottawa, Ontario, Canada

3. Fraser Institute, Vancouver, British Columbia, Canada

4. Canadian PKU and Allied Disorders Inc, Toronto, Ontario, Canada

Funder

No funding

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21678707.2024.2313766

Reference60 articles.

1. Medical products for rare diseases and conditions [internet]. Silver Spring (MD): Food and Drug Administration; 2022 May 12 [cited 2023 Dec 18]. Available from: https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions

2. Orphan incentives [Internet]. Amsterdam: European Medicines Agency;no date [cited 2023 Dec 18]. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation/orphan-incentives

3. Orphan drug designation [Internet]. Woden (ACT): Australian Government; 2018 Aug [cited 2023 Dec 18]. Available from: https://www.tga.gov.au/sites/default/files/orphan-drug-designation.pdf

4. Government of Canada improves access to affordable and effective drugs for rare diseases [internet]. Ottawa (ON): Government of Canada; 2023 Mar 22 [cited 2023 Dec 18]. Available from: https://www.canada.ca/en/health-canada/news/2023/03/government-of-canada-improves-access-to-affordable-and-effective-drugs-for-rare-diseases.html

5. Canada falls behind in new drug submissions compared with the United States and Europe